CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ARET0231 | COG | A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma | Pediatric CIRB | Completed |
| ACCL0935 | COG | Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk | Pediatric CIRB | Completed |
| ACNS0831 | COG | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| PED-CITN-01 | Pediatric CITN | 3CI Study: Childhood Cancer Combination Immunotherapy. Phase 1b and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers | Pediatric CIRB | Completed |
| AEWS0621 | COG | Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma | Pediatric CIRB | Completed |
| PEPN21EHR/PBTC-N15 | Pediatric CITN | Pilot Study to Enable Electronic Laboratory Data Transfer into Medidata Rave | Pediatric CIRB | Completed |
| PEPN2121 | PEP-CTN | A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Pediatric CIRB | Available to Open |
| ANBL00P3 | COG | A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone | Pediatric CIRB | Completed |
| AAML1031 | COG | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | Pediatric CIRB | Available to Open |
| ASCT0431 | COG | A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Selected Patients with CR1 and CR2 ALL: A Groupwide Phase III Study | Pediatric CIRB | Completed |